|
|
|
|
| LEADER |
00000cam a22000007a 4500 |
| 001 |
SCIDIR_on1399353702 |
| 003 |
OCoLC |
| 005 |
20231120010754.0 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
230921s2023 mau o 000 0 eng d |
| 040 |
|
|
|a SFB
|b eng
|c SFB
|d YDX
|d SFB
|d GZM
|d OPELS
|d OCLCQ
|
| 020 |
|
|
|a 9780323955638
|q (hardcover)
|
| 020 |
|
|
|a 0323955630
|q (hardcover)
|
| 020 |
|
|
|z 9780323955638
|q (hardcover)
|
| 035 |
|
|
|a (OCoLC)1399353702
|
| 050 |
|
4 |
|a QR342
|
| 082 |
0 |
4 |
|a 579.26
|
| 245 |
0 |
0 |
|a Phage Therapy.
|n Part A /
|c Vijai Singh
|
| 264 |
|
1 |
|a Cambridge, MA :
|b Academic Press,
|c 2023.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Progress in molecular biology and translational science,
|x 1877-1173 ;
|v 200
|
| 505 |
0 |
|
|a Front Cover -- Title page -- Copyright -- Contents -- Contributors -- Praface -- Chapter One: Exploring the potential of phage and their applications -- 1 Introduction -- 2 Life cycle of phage -- 3 Applications of phage -- 3.1 Phage for detection of bacterial pathogens -- 3.2 Phage therapy for bacterial infections -- 3.3 Phage in food industry -- 3.4 Phage clinical trails -- 3.5 Directed evolution and optimization of phage for enhanced therapy -- 4 Conclusion and future remarks -- Acknowledgements -- References -- Chapter Two: Isolation, screening and characterization of phageIsolation, screening and characterization of phage -- 1 Introduction -- 2 Become a phage-hunter: phage isolation -- 2.1 Sources for phage isolation -- 2.2 General scheme for phage isolation, with emphasis on jumbo phage -- 2.3 Biased and unbiased isolation methods in phage isolation with highlight on advanced techniques -- 2.4 Purification and amplification -- 3 Phage characterization -- 3.1 Phage screening -- 3.1.1 Host range -- 3.1.1.1 Solid-based methods -- 3.1.1.1.1 Spot test for determination of phage host range. -- 3.1.1.1.2 Relative efficiency of platting -- 3.1.1.2 Liquid-based methods -- 3.1.1.2.1 Microtiter plate host range assay. -- 3.1.1.2.2 High-throughput turbidimetric test. -- 3.1.2 Phage adsorption -- 3.2 Morphological characterization -- 3.2.1 Phage plaque morphology -- 3.2.2 Virion structure morphology -- 3.2.2.1 Transmission electron microscopy -- 3.2.2.2 Scanning electron microscopy -- 3.2.2.3 Atomic force microscopy -- 3.2.2.4 Cryo-electron microscopy -- 3.3 Biological characterization -- 3.3.1 One-step growth curve -- 3.3.2 Physical and chemical stability -- 3.3.2.1 Temperature stability -- 3.3.2.2 UV stability -- 3.3.2.3 Chemical stability -- 3.3.2.3.1 pH stability. -- 3.3.2.3.2 Salinity and ions -- 4 Genomic characterization.
|
| 505 |
8 |
|
|a 4.1 Phage genome from extraction to annotation -- 4.2 Further screening of the phage genome -- 4.2.1 Safety -- 4.2.2 Temperate lifecycle gene-markers -- 4.2.3 tRNA and ncRNA genes -- 4.2.4 Holin-lysin lysis system -- 4.2.5 Polysaccharide depolymerases -- 4.2.6 Phage packaging mechanism -- 4.2.7 Regulator elements: promoters and terminators -- 4.3 Phage genome visualization and comparison -- 4.4 Phage phylogenetic analysis -- 4.4.1 At family level -- 4.4.2 At genus and species levels -- 5 Conclusion and future remarks -- References -- Further reading -- Chapter Three: Synthetic phage and its application in phage therapy -- 1 Introduction -- 2 Structure -- 2.1 Composition -- 2.2 Morphology -- 3 Classification -- 4 Development of synthetic phage -- 4.1 Homological remerging (HR) -- 4.2 Genetic data rebooting -- 5 Synthetic phages for substance redevelop -- 5.1 Chemical engineering cue in synthetic phage -- 5.2 Physical science cue control by synthetic phage -- 5.3 Multifunctional phage materials -- 6 Synthetic phage library -- 6.1 Reconstruction of synthetic phage -- 6.2 Genetic engineering of synthetic phage -- 7 Production synthetic phage parts from phage genomes -- 7.1 Phage RNA polymerases -- 7.2 Transcriptional regulators -- 7.3 Integrases -- 8 Application -- 8.1 Vaccine -- 8.2 Phage therapy (PT) -- 8.3 Selected protists Cells -- 8.4 Phage display -- 8.5 Nanomaterials -- 8.6 Phages developed through genetic engineering to promote tissue formation -- 8.7 Biofilms -- 8.8 Phage-based affection -- 8.9 Phage in the diagnostic of cancer -- 8.10 Multidrug resistant -- 8.11 Phage-based drug delivery -- 8.12 Phage as anti-infective -- 9 Conflicts in phage remedy of synthetic phage -- 10 Conclusions -- 11 Future with synthetic phage -- References -- Chapter Four: Phage engineering for development of diagnostic tools -- 1 Introduction.
|
| 505 |
8 |
|
|a 3.1.4 Phage LUZ242s Igy peptide and DNA gyrase -- 3.1.5 Summary table -- 3.2 Interactions in Gram-positive bacteria -- 4 Phage lysis of the host -- 5 Modeling for phage therapy -- 5.1 In vitro cell line models -- 5.1.1 Cytotoxicity and pro-inflammatory characteristics -- 5.1.2 Mechanisms of interaction with tissues -- 5.2 Animal models -- 5.2.1 Invertebrate models -- 5.2.2 Vertebrate models -- 5.2.3 Immunogenicity and toxicity in animal models -- 5.3 Clinical trials in humans -- 6 Conclusions -- References -- Chapter Seven: Phage and phage cocktails formulationsPhage and phage cocktails formulations -- 1 Introduction -- 2 Formulation of phage cocktails -- 3 Applications of phage cocktails -- 3.1 Application of phages in oral infections -- 3.2 Application of phages in urinary tract infections -- 3.3 Application of phages in biofilms treatment -- 4 Conclusion and future perspectives -- Conflict of interest -- References -- Chapter Eight: Phages for treatment of Escherichia coli infectionsPhages for treatment of Escherichia coli infections -- 1 Introduction -- 2 T4-related phages for E. coli therapy -- 2.1 T4-related viruses infecting pathogenic E. coli strains -- 2.2 Characterisation of T4-related viruses for phage therapy -- 2.3 Isolation of bacteriophages from environmental sources -- 2.4 Large-scale phage preparation -- 2.5 Pharmaceutical formulation for phages -- 2.6 Evaluation of T4-related bacteriophage preparations in animal models -- 2.7 Case reports and clinical trials -- 2.8 Phage therapy against pathogenic E. coli: current state and outlook for the future. -- 3 Phage therapy of E. coli O157:H7 -- 3.1 Introduction to E. coli O157:H7 -- 3.2 General considerations for phages against E. coli O157:H7 -- 3.3 Bacteriophages in food processing -- 3.4 Phage therapy in animals affected by E. coli O157:H7 -- 4 Phage therapy -- HGT implications.
|
| 505 |
8 |
|
|a 5 Conclusions -- References -- Chapter Nine: Phages for treatment of Klebsiella pneumoniae infections Phages for treatment of Klebsiella pneumoniae infections -- 1 Introduction -- 2 Know your enemy: K. pneumoniae -- 3 Limitations of antibiotic therapy for K. pneumoniae infections -- 4 Phage therapy of K. pneumoniae -- 4.1 Isolation of K. pneumoniae phages -- 4.2 Morphotypes and taxonomy K. pneumoniae phages -- 4.3 Forms of therapeutic K. pneumoniae phages -- 4.4 In vitro characterization of K. pneumoniae phages -- 4.5 In vivo experiments of phage therapy against K. pneumoniae -- 4.6 Clinical studies on cases treated with Klebsiella phages -- 4.7 Challenges in phage therapy for K. pneumoniae -- 5 Conclusion -- References -- Chapter Ten: Phages for treatment of Salmonella spp infection -- 1 Introduction -- 2 Conventional treatment vs phage therapy -- 3 Rapid screening and detection methods associated with bacteriophage for Salmonella -- 4 Phages as a tool against Salmonella infections -- 4.1 Salmonella phages -- 4.2 Commercially available phage products and regulatory status -- 4.3 Salmonella endolysins -- 5 Challenges in using phages -- 6 Future prospects -- 7 Conclusion -- Acknowledgments -- References -- Chapter Eleven: Phages for treatment of Staphylococcus aureus infection -- 1 Introduction -- 2 Identification, morphology and genomic characteristics of phages infecting S. aureus -- 2.1 Organization of S. aureus phages genomes -- 2.2 Structure and genome of phage K -- 2.3 Novel Staphylococcal phages with unique morphology and broad host range -- 2.3.1 Phage JD219 -- 2.3.2 Phages V1SA19, V1SA20, and V1SA22 -- 3 Phage cocktail development against S. aureus -- 3.1 APTC-C-SA01: A novel bacteriophage cocktail for S. aureus and MRSA Biofilms -- 3.2 Phage cocktail AB-SA01 targeting planktonic and biofilm cultures of S. aureus.
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 650 |
|
0 |
|a Molecular biology.
|
| 650 |
|
0 |
|a Bacteriophages.
|
| 700 |
1 |
|
|a Singh, Vijai,
|e editor.
|
| 830 |
|
0 |
|a Progress in molecular biology and translational science ;
|v 200.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/bookseries/18771173/200
|z Texto completo
|
